INC Research adds James Featherstone, Janet Baldwin, Nathalie Doize & Alastair MacDonald to team
INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC's continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.
“Healthcare stakeholders are increasingly seeking real-world evidence to support regulatory, reimbursement and prescribing decisions,” said Christian Tucat, MBA, executive vice president, RWLP and Global Consulting. “It’s never too early to have a commercial plan in drug development, and that’s why we’ve continued to grow our team. The leadership we’ve added in RWLP and Global Consulting have extensive industry connections and understand the complexities of Late Phase studies, moving new therapies from a controlled and experimental environment of a clinical trial to a real-world situation, and then to market. By beginning with the end in mind, we ensure we gain the right outcome for our sponsors as well as for patients, physicians, payers and regulators.”
The newly appointed experts to INC’s RWLP and Global Consulting teams include:
- James Featherstone, senior vice president, Strategy Consulting, has 25 years of experience in the healthcare industry. Dr. Featherstone served most recently as COO of Healthcare at Home, the U.K.'s largest home healthcare provider. Prior to that, he was senior vice president at Quintiles where he was responsible for the development of their strategy consulting business in Europe and global ‘Commercial’ strategy for the organization including Commercial operations in emerging markets. Dr Featherstone’s experience includes portfolio optimization, market access and commercialization strategy.
- Janet Baldwin, vice president, Real World & Late Phase, head of North America Operations, has more than 30 years of drug development experience, working for both large pharma and CROs. For the past 10 years, she has served in a variety of roles, including head of Late Phase Project Management and Analytics at Parexel, where she was responsible for designing and overseeing observational (both prospective and retrospective), Phase IV interventional, large Outcomes Studies and Expanded Access Programs (EAPs). Ms. Baldwin’s experience also includes serving as a principal investigator in direct to patient access research using pharmacy data and as Global Head of Clinical Operations and Observational Research at another global CRO.
- Nathalie Doize, vice president, Real World & Late Phase, Head of Europe and Asia/Pacific Operations, has more than 25 years of experience working in clinical research for both pharma and CROs. Prior to joining INC, she was vice president, Global Operations at Regist-Mapi, where she was responsible for management and oversight of operational teams globally and provided strategic and operational expertise in the design and conduct of post-approval and commercialization programs for pharmaceutical products such as PASS, registries, RMP, observational and non-interventional studies.
- Alastair MacDonald, executive director, Real World & Late Phase, has 25 years of experience in the biopharmaceutical development sector. Prior to joining INC, he was global delivery director for Medical Evidence and Observational Research at AstraZeneca with responsibility for the generation of evidence in both pre- and post-approval drugs required to support core clinical development programs and prepare for reimbursement.
INC’s Global Consulting team provides global advisory and implementation support service for the biopharmaceutical industry. Led by a senior team, the unit is committed to working with customers to deliver innovative and practical solutions that support their business needs from concept through development to commercialization.